All In Biotech

Drug Trial Radar · NCT06743438

Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB

Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With HBeAg-positive or HBeAg-negative Chronic Hepatitis B - a Multicenter, Open-label Follow-up Study

Last checked: Nov 20, 2026Latest source record: Dec 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

640

Actual

Start

Mar 10, 2022

Primary completion

Jun 30, 2024

Study completion Sep 30, 2029

Sponsor

Sponsor type
Industry
First posted
Dec 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Tenofovir amibufenamide (TMF) is a novel prodrug of tenofovir that has been widely used in mainland China for the treatment of chronic hepatitis B (CHB). The previous registrational study (NCT03903796) has established the non-inferior virologic efficacy of TMF to tenofovir disoproxil fumarate (TDF), while demonstrating higher rates of alanine aminotransferase (ALT) normalization and improved bone and renal safety profiles. This study presented the long-term efficacy and safety of TMF in a phase IV study.

Conditions

  • Hepatitis B, Chronic

Interventions

  • Tenofovir Amibufenamide(TMF)Drug

    Once-daily oral dose of 25 mg TMF were maintained in all participants

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation the percentage of Participants with Hepatitis B Virus (HBV) DNA lower than in the central laboratoryTime frame: week (144+)96

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.